Reviewer’s report

Title: Continuous intravenous infusion of remifentanil improves the experience of parturient undergoing repeated cesarean section under epidural anesthesia, a prospective, randomized study

Version: 2 Date: 23 Nov 2019

Reviewer: Ohashi Yayoi

Reviewer's report:

Thank you for revising your manuscript according to my comments.

P3, "Many studies have shown that remifentanil (an off label drug for parturient) has less adverse neonatal or maternal effects during cesarean section". - This statement doesn't quite include my concern mentioned last time. I would suggest you to state that "Whilst remifentanil is an off label drug for parturients and some serious adverse effects with remifentanil have previously been reported, it has been recently said that remifentanil is effective, has less adverse effects compared to other opioid medications and is safe to use in controlled circumstances." - reference1) Remifentanil patient-controlled analgesia in labour: six-year audit of outcome data of the RemiPCA SAFE Network (2010-2015). International Journal of Obstetric Anesthesia 2019; 39, 12-21. reference2) Wilson et al. Intravenous remifentanil patient-controlled analgesia versus intramuscular pethidine for pain relief in labour (RESPITE): an open-label, multicentre, randomised controlled trial. Lancet 2018; 392: 662-72. reference3) Radhika et al. Remifentanil versus fentanyl for intravenous patient-controlled labour analgesia: an observational study. Canadian Journal of Anesthesia 2012; Vol.59: 246-254

P4 Method, Please insert a sentence "RR was measured by carbon dioxide sampling". Therefore readers know that you monitor patients appropriately with the use of remifentanil.

P7 Result, Ketamine administration did not differ despite the VAS was lower in Group R. - you answered my question. Please include your comment/answer in the discussion part.

Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.

Yes

Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.

Unable to assess

Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.

Yes
Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

Not relevant to this manuscript

Quality of written English
Please indicate the quality of language in the manuscript:

Acceptable

Declaration of competing interests
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I declare that I have no competing interests.

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal.